Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- Daiichi Sankyo, Perosphere to Develop Anticoagulant Reversal Agent for Edoxaban
May 2, 2013
- Anticancer Agent Xtandi Receives Positive Opinion for Marketing Approval by EMA: Astellas
May 2, 2013
- Boehringer to Enter Oncology Market, Hire 100 MRs in Japan
May 2, 2013
- Boehringer Chief Says Japan Business Successful
May 2, 2013
- Astellas Vice President Miyokawa to Be Promoted to Representative Director
May 2, 2013
- Novartis Investigating Employee Involvement in Retracted Diovan Papers
May 1, 2013
- Torii Aims for Sales of 63 Billion Yen in FY2015, Expanding Allergen Field
May 1, 2013
- Torii to Launch Anti-HIV Drug Stribild Combination Tablets on May 14
May 1, 2013
- Eisai to Establish New Parenteral Plant to Manufacture Methycobal in China
May 1, 2013
- With Mucosta Pursuing Diquas, New Drugs Have Growing Presence in Market for Dry Eye Treatments
April 30, 2013
- UMN to Open Japan’s Biggest Biopharmaceutical Contract Manufacturing Facility; Success or Failure Could Determine the Future of this Business in Japan
April 30, 2013
- Ethical Drug Production to Exceed 12 Trillion Yen in 2020: Yano Research Institute
April 30, 2013
- Sandoz K.K. Applies for Gran Biosimilar
April 26, 2013
- Daiichi Sankyo Begins Nimotuzumab PIII Trials for Lung and Gastric Cancers
April 26, 2013
- Boehringer Filed NDA for Afatinib in Japan: Chairman
April 26, 2013
- Takeda Files NDA for Fixed-Dose Combination of Azilva/Amlodipine in Japan
April 26, 2013
- Edoxaban Will Be Key to Achieving Targets in Daiichi Sankyo’s New 5-Year Business Plan
April 26, 2013
- Takeda Initiates Voluntary Partial Recall for Azilva due to Incorrect Expiry Date on Packaging Carton
April 25, 2013
- GSK Files NDA for LAMA/LABA Combination Drug for COPD Treatment
April 24, 2013
- Shionogi Revises Profit Forecasts for FY2012
April 24, 2013
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…